Corrientes

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Familial hypercholesterolaemia3 trials
• Stroke3 trials
• Heart failure1 trial

Phase

• Phase 34 trials
• Phase 42 trials

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals6 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  LATAM LOWERS LDL-C

  NCT06501443· Phase 4· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Familial hypercholesterolaemia1 recruiting

Closed trials

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

  NCT04023227· Phase 4· Novartis Pharmaceuticals· Source